Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
48-Hour Action Plan: Patient Safety First, Managed Transparency Second Core Decision (Stated Up Front) We report to regulators immediately—voluntarily—and we disclose on the earnings call. The math is brutal and clear: ~500 patients could develop liver failure over 5 years at current prescribing rates (4M ÷ 8,000).Read the full answer
This is a defining moment for my leadership and the company. The pressure from the board to "wait for more data" is a trap that has destroyed pharmaceutical companies in the past (e.g., Merck with Vioxx). Hiding a safety signal to manipulate stock price is securities fraud and criminal negligence.Read the full answer